Astrazeneca Plc (AZN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 12,938,000 | 12,679,000 | 12,024,000 | 11,492,000 | 11,416,000 |
| Cost of Goods | 2,183,000 | 2,218,000 | 2,308,000 | 2,095,000 | 1,960,000 |
| Gross Profit | 10,755,000 | 10,461,000 | 9,716,000 | 9,397,000 | 9,456,000 |
| Operating Expenses | 8,009,000 | 7,346,000 | 8,482,000 | 7,443,000 | 7,000,000 |
| Operating Income | 2,746,000 | 3,115,000 | 1,234,000 | 1,954,000 | 2,456,000 |
| Interest Expense | 443,000 | 413,000 | 445,000 | 392,000 | 431,000 |
| Other Income | 94,000 | 98,000 | 108,000 | 90,000 | 63,000 |
| Pre-tax Income | 2,397,000 | 2,800,000 | 897,000 | 1,652,000 | 2,088,000 |
| Income Tax | 469,000 | 620,000 | -62,000 | 274,000 | 268,000 |
| Net Income Continuous | 1,928,000 | 2,180,000 | 959,000 | 1,378,000 | 1,820,000 |
| Minority Interests | -1,000 | -1,000 | 1,000 | -4,000 | -2,000 |
| Net Income | $1,927,000 | $2,179,000 | $960,000 | $1,374,000 | $1,818,000 |
| EPS Basic Total Ops | 1.24 | 1.41 | 0.62 | 0.89 | 1.17 |
| EPS Basic Continuous Ops | 1.24 | 1.41 | 0.62 | 0.89 | 1.17 |
| EPS Diluted Total Ops | 1.24 | 1.40 | 0.62 | 0.88 | 1.17 |
| EPS Diluted Continuous Ops | 1.24 | 1.40 | 0.62 | 0.88 | 1.17 |
| EBITDA(a) | $4,119,000 | $4,468,000 | $2,216,000 | $3,326,000 | $3,795,000 |